MAM
WST icon

Martingale Asset Management’s West Pharmaceutical WST Stock Holding History

Martingale Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-28,411
Closed -$8.59M – 906
2022
Q2 		$8.59M Sell
28,411
-29,521
-51% -$9.61M 0.16% 153
2022
Q1 		$23.8M Sell
57,932
-41,078
-41% -$16.1M 0.36% 109
2021
Q4 		$46.4M Sell
99,010
-37,143
-27% -$16M 0.59% 60
2021
Q3 		$57.8M Sell
136,153
-41,177
-23% -$17.4M 0.76% 37
2021
Q2 		$63.7M Buy
177,330
+2,583
+1% +$853K 0.73% 41
2021
Q1 		$49.2M Buy
174,747
+30,929
+22% +$8.85M 0.57% 67
2020
Q4 		$40.7M Buy
143,818
+77,552
+117% +$21.8M 0.46% 84
2020
Q3 		$18.2M Buy
66,266
+56,357
+569% +$14.9M 0.22% 133
2020
Q2 		$2.25M Buy
9,909
+5,201
+110% +$1.02M 0.03% 493
2020
Q1 		$718K Sell
4,708
-397
-8% -$61.1K 0.01% 746
2019
Q4 		$768K Hold
5,105
– – 0.01% 812
2019
Q3 		$725K Buy
5,105
+2,404
+89% +$331K 0.01% 824
2019
Q2 		$339K Sell
2,701
-1,001
-27% -$118K ﹤0.01% 944
2019
Q1 		$409K Buy
+3,702
New +$385K ﹤0.01% 908
2016
Q4 		– Sell
-11,311
Closed -$843K – 1018
2016
Q3 		$843K Sell
11,311
-2,901
-20% -$230K 0.01% 723
2016
Q2 		$1.08M Sell
14,212
-4,701
-25% -$342K 0.02% 481
2016
Q1 		$1.31M Sell
18,913
-800
-4% -$48.1K 0.03% 414
2015
Q4 		$1.19M Sell
19,713
-1,003
-5% -$60.3K 0.03% 426
2015
Q3 		$1.12M Sell
20,716
-2,201
-10% -$128K 0.03% 436
2015
Q2 		$1.33M Sell
22,917
-1,000
-4% -$55.8K 0.03% 421
2015
Q1 		$1.44M Sell
23,917
-1,700
-7% -$90.6K 0.03% 402
2014
Q4 		$1.36M Sell
25,617
-1,000
-4% -$50K 0.04% 409
2014
Q3 		$1.19M Sell
26,617
-1,416
-5% -$60.2K 0.04% 420
2014
Q2 		$1.18M Sell
28,033
-200
-0.7% -$8.56K 0.04% 462
2014
Q1 		$1.24M Hold
28,233
– – 0.04% 417
2013
Q4 		$1.39M Sell
28,233
-1,805
-6% -$84.5K 0.05% 417
2013
Q3 		$1.24M Sell
30,038
-11,800
-28% -$450K 0.04% 426
2013
Q2 		$1.47M Buy
+41,838
New +$1.38M 0.05% 356

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Martingale Asset Management's WST Position: Q3 2022 in Review

Martingale Asset Management sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 28,411 shares — an estimated $8.59M sold.

Martingale Asset Management first reported a position in WST in Q2 2013 and held it in 28 quarters. The position peaked at $63.7M in Q2 2021. 639 funds tracked by Wall St. Rank hold WST as of Q3 2022.

  • Martingale Asset Management reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Martingale Asset Management sold 28,411 West Pharmaceutical shares in Q3 2022, an estimated $8.59M.
  • Martingale Asset Management first reported a position in West Pharmaceutical in Q2 2013 and held it in 28 quarters.
  • Martingale Asset Management's West Pharmaceutical position peaked at $63.7M in Q2 2021.
  • 639 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Martingale Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.